The UK and US have concluded a major commercial pact that will preserve zero import taxes on UK drug exports going into the US market.
Key Provisions of the Deal
As part of the deal, the UK has pledged to increase spending on pharmaceuticals through the public health system. This commitment guarantees that tariffs on these key goods will be held at zero for a period of the next three years.
This deal is in response to earlier threats to significantly raise duties on branded drug products, with figures floated as high as 100%.
"This deal between the Britain bolsters the global environment for new treatments and establishes much-needed equity to U.S.–U.K. pharmaceutical trade," a release said.
Commercial Impact
Pharmaceuticals constitute one of the Britain's biggest exports to the US, which is easily the primary buyer for major UK drugmakers.
Trade data reveal that in the year to the end of the third quarter, the UK exported pharmaceutical products worth over eleven billion pounds to the US. This value represented a significant portion of total UK exports in that span.
"This agreement safeguards employment, increases investment and paves the way for the UK to establish itself as a international leader for life sciences," the Business and Trade Secretary remarked.
Key UK Commitments
The deal entails several specific commitments from the British government:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it judges new medicines to be unaffordable by 25%.
- Higher Drug Budget: There is a aim to double overall health service expenditure on medicines from 0.3% of the national economy to 0.6% over the coming ten years.
- Payback Limit: The percentage pharmaceutical firms must pay back to the NHS to control costs will be capped at 15%. Last year, refunds topped twenty percent.
Recent Tensions
The pact takes place against a protracted dispute between the sector and the British authorities over spending levels and approval rates.
The disagreement were exacerbated by claims that American patients were paying several times more for the same drugs than people in the Britain and the EU.
Recently, several significant pharmaceutical investments in the UK have been delayed or cancelled, while substantial expansions have been directed toward US facilities.
A senior figure publicly accepted that the NHS had to spend more on medicines, noting that its budget allocation on drugs had decreased as a share of its overall budget over the last ten years.
